MediaPharma Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1

Employees

  • Latest Deal Type
  • M&A

MediaPharma General Information

Description

Developer of immuno-oncology drugs created for the treatment of cancer and other severe diseases with high medical needs. The company focuses on the research and development of humanized monoclonal antibodies, antibody-drug conjugates and therapeutic proteins for cancers that have become resistant to previous drug regimens, enabling physicians to provide effective treatment for cancer through oncology drugs.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Via Colonnetta, 50/A
  • 66013 Chieti
  • Italy
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Via Colonnetta, 50/A
  • 66013 Chieti
  • Italy

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MediaPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 31-Dec-2021 Completed Generating Revenue
3. Early Stage VC Completed Generating Revenue
2. Secondary Transaction - Private 01-Mar-2021 $451K Completed Generating Revenue
1. Early Stage VC 01-Oct-2012 $451K $451K Completed Generating Revenue
To view MediaPharma’s complete valuation and funding history, request access »

MediaPharma Patents

MediaPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3995829-A1 Lgals3bp as a diagnostic, prognostic, and therapeutic biomarker in covid-19 and other cytokine storm conditions Inactive 09-Nov-2020
WO-2022096732-A1 Lgals3bp as a diagnostic, prognostic, and therapeutic biomarker in covid-19 and other cytokine storm conditions Inactive 09-Nov-2020
EP-3880706-A1 Bispecific antibodies directed against human 90k and either endosialin or her3 Inactive 12-Nov-2018
WO-2020099235-A1 Bispecific antibodies directed against human 90k and either endosialin or her3 Inactive 12-Nov-2018
EP-3773739-A1 Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer Pending 12-Apr-2018 A61K47/6849
To view MediaPharma’s complete patent history, request access »

MediaPharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MediaPharma Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Filas Venture Capital Minority
Invent (Rome) Venture Capital Minority
Lazio Innova Venture Capital Minority
TOTO Costruzioni Generali Corporation Minority
To view MediaPharma’s complete investors history, request access »

MediaPharma FAQs

  • When was MediaPharma founded?

    MediaPharma was founded in 2009.

  • Where is MediaPharma headquartered?

    MediaPharma is headquartered in Chieti, Italy.

  • What is the size of MediaPharma?

    MediaPharma has 1 total employees.

  • What industry is MediaPharma in?

    MediaPharma’s primary industry is Drug Discovery.

  • Is MediaPharma a private or public company?

    MediaPharma is a Private company.

  • What is MediaPharma’s current revenue?

    The current revenue for MediaPharma is .

  • How much funding has MediaPharma raised over time?

    MediaPharma has raised $451K.

  • Who are MediaPharma’s investors?

    Filas, Invent (Rome), Lazio Innova, and TOTO Costruzioni Generali have invested in MediaPharma.

  • When was MediaPharma acquired?

    MediaPharma was acquired on 31-Dec-2021.

  • Who acquired MediaPharma?

    MediaPharma was acquired by Fusion Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process